PharmaFocus Today – Page 17 – media

The 14th Forum on Innovation and Development of the Pharmaceutical Industry Successfully Held in Shanghai

From June 24 to 25, during the 23rd World Pharmaceutical Raw Materials China Exhibition, the 14th Forum on Innovation and Development of the Pharmaceutical Industry was successfully held in Shanghai. This forum conducted special discussions on hot topics such as the trends of economic and trade restriction measures of the U.S. Trump administration, underwriting and risk analysis of the biopharmaceutical industry chain, review and analysis of China’s pharmaceutical industry development during the “14th Five-Year Plan” and outlook on the development situation during the “15th Five-Year Plan”, the impact and trend prediction of new policies on the pharmaceutical industry, the main characteristics of current pharmaceutical industry development, the development status of China’s generic drug industry, the trends and strategies of pharmaceutical companies entering emerging markets, countermeasures for Chinese export enterprises under the background of Sino-U.S. trade frictions, and the core advantages of industrial parks. Luo Yang, Deputy Secretary-General of the China ...
- Source: drugdu
- 67
- July 7, 2025
Muhammad Iqbal Chaudhry, Coordinator General of the Standing Committee on Scientific and Technological Cooperation of the Organization of Islamic Cooperation (OIC-COMSTECH), and his delegation paid a visit to the China Chamber of Commerce for Import and Export of Medicines and Health Products (CCCMHPIE).

On the afternoon of June 10, a delegation of over 10 people, including Professor Muhammad Iqbal Chaudhry, Coordinator General of the Cooperation-Ministerial Standing Committee on Scientific and Technological Cooperation of the Organization of Islamic Cooperation (OIC-COMSTECH), Maggie Lowe, an official from the Commercial Section of the Embassy of Pakistan in China, and Professor Liu Xinmin, Advisor on Traditional Medicine of the World Health Organization and Coordinator for Traditional Chinese Medicine of OIC-COMSTECH, visited the China Chamber of Commerce for Import and Export of Medicines and Health Products (CCCMHPIE). They held discussions and exchanges with Secretary Meng Dongping of the Chamber and other representatives. The two sides engaged in extensive and lively exchanges on strengthening cooperation between China and the Organization of Islamic Cooperation in the field of traditional medicine under the framework of the SCO Traditional Medicine Industry Alliance, promoting China-Pakistan cooperation in traditional medicine, and facilitating the integration of ...
- Source: drugdu
- 61
- July 7, 2025
CCCMHPIE Joins Hands with International Organizations to Build New Access Channels for Pharmaceutical Markets in Low- and Middle-Income Countries — Medicines Patent Pool (MPP) Docking and Exchange Event Successfully Held in Shanghai

On June 25, 2025, the “Exchange Meeting for Assisting Chinese Enterprises in Entering Pharmaceutical Markets of Low – and Middle – Income Countries” co – hosted by the China Chamber of Commerce for Import and Export of Medicines and Health Products (CCCMHPIE) and the Medicines Patent Pool (MPP) – a global health organization supported by the United Nations – successfully concluded at the Shanghai New International Expo Center. The event gathered experts from MPP, the United Nations International Drug Purchase Facility (UNITAID), and over 50 Chinese pharmaceutical companies to jointly explore strategic paths for tapping into the global pharmaceutical blue – ocean market with a population of 4.5 billion through innovative international cooperation mechanisms. President Zhou Hui of CCCMHPIE and Dr. Judith Federhofer, Director of Business Development at MPP, attended the forum and delivered speeches. Director Zhang Beibei of the Legal and Comprehensive Department presided over the forum. I. Breaking ...
- Source: drugdu
- 64
- July 7, 2025
The Path of the Biotechnology Industry to Net Zero

The pharmaceutical industry took some time to put sustainable development on the management agenda. However, the industry is now going all out to catch up – with strong support from Zeta. This solution provider is helping the pharmaceutical industry with its low-carbon transformation through its net-zero roadmap and a new business line. Since the EU announced the “European Green Deal”, one thing has become clear: all industries must work together to achieve the goal of zero emissions. The pharmaceutical industry has been slow to progress. But now, pressure from investors and shareholders has prompted leaders in the pharmaceutical and biotechnology industries to pick up the pace. Green energy, sustainable supply chains, and decarbonization of production and bases – many companies are now embarking on the path of green transformation. This can be seen from the sustainable development goals set by industry giants such as Novartis, GSK, or Roche, as well ...
- Source: drugdu
- 63
- July 7, 2025
the first of its kind to achieve the primary endpoint of mid-term analysis in nasopharyngeal carcinoma stage III clinical trials with iza bene

On the evening of July 2nd, Baili Tianheng announced that its independently developed EGFR × HER3 dual antibody ADC (iza bene), which is a first in class, new concept, and the only one to enter the Phase III clinical stage, has reached the primary endpoint in the Phase III clinical trial of nasopharyngeal carcinoma (study protocol number: BL-B01D1-303). The indication is for recurrent or metastatic nasopharyngeal carcinoma that has been previously treated with PD-1/PD-L1 monoclonal antibodies and has failed at least two lines of chemotherapy (at least one line containing platinum). The announcement shows that Iza bren is conducting over 40 clinical trials targeting multiple types of tumors in China and the United States. As of now, Iza bren has 5 indications included in the breakthrough treatment list by the Drug Evaluation Center of the National Medical Products Administration. Baili Tianheng presented Phase I research data on Iza bren treatment ...
- Source: drugdu
- 88
- July 4, 2025
Gout treatment welcomes new choices! Changchun High tech’s first domestically approved injection of Fuxinqibai monoclonal antibody for market launch

On the evening of July 2nd, Changchun High tech announced that its subsidiary Jinsai Pharmaceutical, which is controlled by the company, has obtained approval from the National Medical Products Administration for the injection of Fuxinqibai monoclonal antibody (formerly known as Jinna monoclonal antibody for injection). This drug is the first domestically approved IL-1 inhibitor for the treatment of acute attacks of gouty arthritis, and its precise and long-lasting anti-inflammatory advantages will bring new treatment options for gout patients. It is reported that Fuxinqibai monoclonal antibody for injection is a new type of fully human anti-IL-1 β monoclonal antibody drug developed by the company. It belongs to the first class of therapeutic biological products and can specifically bind to human IL-1 β, block the production of inflammatory mediators induced by IL-1 β. It is suitable for acute attacks of gouty arthritis in adults who are contraindicated, intolerant or lack efficacy of ...
- Source: drugdu
- 78
- July 4, 2025
this is the path to carbon neutrality

Is it possible to achieve carbon – dioxide – free operation of pharmaceutical warehouses? The answer is yes. United Therapeutics, a biopharmaceutical company, has built a Good Manufacturing Practice (GMP) – compliant warehouse in North Carolina, southern United States, which is worthy of being called a milestone project. Next, let’s take a closer look at the details. Generally, GMP – compliant pharmaceutical warehouses are not energy – efficient buildings. The temperature – control system needs to run continuously, the air humidity needs to be kept stable, and the whole system also needs to go through strict verification. The power consumption of the air – conditioning system is huge, and when a cryogenic area needs to be set up for sensitive active ingredients, the energy consumption is doubled. All in all, these conditions are not ideal for designing a net – zero energy – consumption building. Nevertheless, it is indeed feasible. ...
- Source: drugdu
- 55
- July 4, 2025
Dizal (Jiangsu) Pharmaceutical Co., Ltd. Voluntary Disclosure of Announcement Regarding Accelerated Marketing Approval of Suvoderm® by the U.S. FDA

Dizal (Jiangsu) Pharmaceutical Co., Ltd. (hereinafter referred to as the “Company”) has officially received approval from the U.S. Food and Drug Administration (FDA) for the New Drug Application (NDA) of its independently developed Sulvoteran® (English trade name: ZEGFROVY®, generic name: Sulvotinib Tablets). It is indicated for adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20 insertion mutations (Exon20ins) as detected by an FDA-approved testing kit, whose disease has progressed during or after platinum-containing chemotherapy. Sulvoteran® was approved for marketing through the Priority Review process, becoming the world’s first and currently the only domestically innovative drug approved in the U.S. for EGFR Exon20ins NSCLC. It has achieved significant innovations in molecular design at the source, breaking through intractable targets, and is China’s first globally first-in-class innovative drug independently developed and approved in the U.S. I. Information Related to the Drug ...
- Source: drugdu
- 65
- July 4, 2025
Rare, Recurrent, and Still a Challenge

Despite the rising incidence of rheumatoid arthritis (RA), extra-articular manifestations have become rare in the era of modern treat-to-target therapy. However, they still present clinical challenges — particularly in the case of rheumatoid nodules. In addition to the need to rule out serious differential diagnoses and address potential complications, especially those involving the lungs, these recurrent inflammatory granulomas can affect daily life not only cosmetically but also functionally. Christopher Edwards, MD, professor of rheumatology at University Hospital Southampton in Southampton, England, discussed the clinical relevance and management of rheumatoid nodules during the 2025 Annual Meeting of the European Alliance of Associations for Rheumatology. When Edwards began his career in rheumatology, the presence of rheumatoid nodules was considered a key diagnostic criterion for RA. If not found on the hands, clinicians often examined the elbows and Achilles tendons, which are also common sites. Histologically, rheumatoid nodules are granulomatous inflammatory lesions that ...
- Source: drugdu
- 62
- July 4, 2025
FDA Vaccine Official Restricted COVID Vaccine Approvals Against the Advice of Agency Staff

A top official at the Food and Drug Administration recently overruled government scientists on the availability of two COVID-19 vaccinesWASHINGTON (AP) — The government’s top vaccine official working under Health Secretary Robert F. Kennedy Jr. recently restricted the approval of two COVID-19 vaccines, disregarding recommendations from government scientists, according to federal documents released Wednesday. The new memos from the Food and Drug Administration show how the agency’s vaccine chief, Dr. Vinay Prasad, personally intervened to place restrictions on COVID shots from vaccine makers Novavax and Moderna. Both vaccines were approved by the FDA in May after months of analysis by rank-and-file FDA reviewers. But internal correspondence show Prasad disagreed with staffers who planned to approve the shots for everyone 12 and older, similar to previous COVID vaccines. The scientists had concluded the benefit from the vaccines and the risk of COVID-19 outweighed the risk of possible side effects, which are ...
- Source: drugdu
- 61
- July 4, 2025

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.